Supplementary Table 6.
Laboratory Characteristics Among Hospitalized Patients With Chronic Liver Disease and COVID-19 (n = 524)
| All-cause mortality status |
P value | ||
|---|---|---|---|
| Alive | Died | ||
| ALT | |||
| Before COVID-19 (n = 374) | 27 (18–40) | 21 (15–33) | .075 |
| At COVID-19 diagnosis (n = 467) | 35 (22–63) | 31.5 (24–57) | .220 |
| Peak (n = 428) | 50 (28–104) | 40.5 (23–88) | .307 |
| Delta-ALT (n = 410) | 0 (0–27.5) | 3 (0–22.5) | .278 |
| AST | |||
| Before COVID-19 (n = 375) | 27 (20–40) | 32 (21–65) | .178 |
| At COVID-19 diagnosis (n = 463) | 50 (30–81.5) | 63.5 (38–63.5) | .021 |
| Peak (n = 428) | 65 (39–120) | 92.5 (51.5–225) | .001 |
| Delta-AST (n = 406) | 5 (0–35) | 22 (0–123) | .075 |
| ALP | |||
| Before COVID-19 (n = 373) | 89 (69–128) | 109 (75–152) | .032 |
| At COVID-19 diagnosis (n = 467) | 83 (63–119) | 91.5 (63–91.5) | .374 |
| Peak (n = 427) | 99 (70–158.5) | 131 (79–235) | .001 |
| Delta-ALP (n = 413) | 8.5 (0–48) | 5.0 (0–87) | .330 |
| Bilirubin | |||
| Before COVID-19 (n = 372) | 0.5 (0.4–0.8) | 0.7 (0.5–1.7) | .004 |
| At COVID-19 diagnosis (n = 467) | 0.6 (0.4–0.9) | 0.8 (0.5–2.2) | <.001 |
| Peak (n = 428) | 0.7 (0.4–1.2) | 1.5 (0.7–4.0) | <.001 |
| Delta-bilirubin (n = 409) | 0.1 (0–0.5) | 0.2 (0–1.6) | .037 |
| MELD score | |||
| Before COVID-19 (n = 276) | 10.0 (7–14) | 11.0 (8–21) | <.001 |
| At COVID-19 diagnosis (n = 375) | 10.5 (7–18) | 16.5 (11–24) | <.001 |
| Peak (n = 291) | 14.0 (8–21) | 21.5 (13–32) | <.001 |
| Delta-MELD (n = 254) | 1.0 (0–4) | 5.0 (0–12.5) | <.001 |
NOTE. Data are expressed as median (interquartile range). Mann-Whitney U test was performed for comparison between groups.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; COVID-19, coronavirus disease 2019.